Company / Capital Expenditures
Stoke Therapeutics, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$670.0K
FY2025
5-year range
$670.0K / $4.0M
FY2021-FY2025
Trend
-58.5%
vs FY2024
Sector context
#130 of 194
Health Care
What the data says
At $670,000, Stoke Therapeutics, Inc.'s capital expenditures ranks #130 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 8 years, ranging from $670,000 in FY2025 to $4M in FY2023.
Based on SEC 10-K filings.
$670,000 in FY2025 with a 5-year CAGR of -8.6%.
Declined from $4M to $670,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -17.7%
- 5-Year CAGR
- -8.6%
- 10-Year CAGR
- -
Sector benchmark
#130 of 194 in Health CareTop 67% of 194This company $670.0K Sector average $117.5M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.6%, indicating a declining trend.
- In FY2025, capital expenditures decreased 58.5% year-over-year.
- Ranks #130 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $670.0K | -58.5% |
| FY2024 | $1.6M | -59.2% |
| FY2023 | $4.0M | +230.2% |
| FY2022 | $1.2M | +0.0% |
| FY2021 | $1.2M | +14.3% |
| FY2020 | $1.1M | -35.8% |
| FY2019 | $1.6M | +74.9% |
| FY2018 | $935.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026